Dr. Barnes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 Eastowne Dr
Chapel Hill, NC 27514Phone+1 984-974-5050Fax+1 919-843-6899
Education & Training
University of North Carolina HospitalsFellowship, Gastroenterology, 2016 - 2017
Brigham and Women's HospitalFellowship, Gastroenterology, 2013 - 2016- University of North Carolina HospitalsResidency, Internal Medicine, 2009 - 2012
University of South Carolina School of MedicineClass of 2009
Certifications & Licensure
NC State Medical License 2009 - 2026
TX State Medical License 2024 - 2024
MA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Clinical Trials
- Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management Start of enrollment: 2024 Jul 24
Roles: Contact
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) Start of enrollment: 2024 Jun 12
Roles: Principal Investigator
Publications & Presentations
PubMed
- Endoscopic assessment of the J pouch in ulcerative colitis: A narrative review.Shintaro Akiyama, Edward L Barnes, Tsubasa Onoda, Naoki Ishikawa, Mamiko Shiroyama
DEN Open. 2025-04-01 - 2 citationsRisankizumab Is Effective for The Management of Crohn's Disease of the Pouch.Maia Kayal, Elizabeth A Spencer, Matthew Smyth, Laura Raffals, Taha Qazi
Inflammatory Bowel Diseases. 2025-03-03 - 1 citationsDiagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic Review.Katherine Falloon, Zahra Dossaji, Pooja Mude, Suha Abushamma, Ashwin Ananthakrishnan
Inflammatory Bowel Diseases. 2025-03-03
Authored Content
- Q&A: Updated AGA Guidance on Managing Post-IPAA PouchitisSeptember 2024
Press Mentions
Weekly Roundup: 14 Health Press Releases You Need to SeeFebruary 14th, 2025- Most Patients on Lilly's Omvoh® (Mirikizumab-Mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two YearsFebruary 7th, 2025
- Q&A: Updated AGA Guidance on Managing Post-IPAA PouchitisSeptember 20th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
